IGM Biosciences acquired by Concentra Biosciences; delisted from Nasdaq

IGM Biosciences, Inc.

Tender offer closed August 13, 2025; 77.53% of shares tendered, all conditions satisfied.
Each share exchanged for $1.247 cash plus one contingent value right (CVR).
Board resigned; Kevin Tang named sole director of surviving corporation.
Trading of IGMS common stock suspended; delisting and deregistration initiated.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.